BGM Group Ltd. Class A Ordinary Shares (BGM)

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach BGM as a Graham-style net-worth exercise first: at the 2026-10-26 close the stock is $8.40, market cap $67.5M, and the FairStock P/B is 4.22. That is not a bargain price for a company with a negative FairStock P/E of -52.50, ROE of -7.41%, and ROCE of -2.18%. The P/E is not meaningful in the usual sense because earnings are negative; the P/B is meaningful and tells me the market is paying a premium to book for poor returns. The D/E of 0.00 is a real positive—no debt in the provided data—but it does not by itself create value. The calculated Piotroski F-Score of 3/9 and Altman Z-Score of 0.88 suggest weak fundamental momentum and limited financial comfort. The 52-week range of $0.23 to $10.80 is extraordinarily wide; at $8.40 the stock is near the top of that range, not the bottom. I cannot identify a durable moat from the provided description: oxytetracycline tablets and APIs are generic-style pharmaceutical/chemical products, and the AI and insurance segments add complexity rather than proven advantage. Growth is unproven: revenue growth and profit growth are N/A, and FairStock assigns no Lynch category because there are only 0 years of filed results versus the 3 needed. For a Buffett-style business, I want consistent earning power, high returns on capital, and a sensible price. BGM currently offers none of those in the supplied numbers. It may be an interesting speculative turnaround, but as a value investment I would require a much larger margin of safety.

In plain English: BGM Group is a small China-based company that sells medicines and chemicals, including oxytetracycline products for animals and people, and it also lists AI and insurance businesses. The business looks weak in the supplied numbers: it is losing money, has a very short reporting record, and the stock has traded between 23 cents and $10.80 in the past year. At $8.40, the price does not look cheap compared with the company’s current losses and weak financial signals.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer